<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="49378">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02463409</url>
  </required_header>
  <id_info>
    <org_study_id>IRB 150497</org_study_id>
    <nct_id>NCT02463409</nct_id>
  </id_info>
  <brief_title>Theophylline as a Treatment for Children With Pseudohypoparathyroidism Type 1a (Albright Hereditary Osteodystrophy)</brief_title>
  <official_title>Effects of Theophylline on cAMP Signaling in Children With Pseudohypoparathyroidism Type 1a</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vanderbilt University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Vanderbilt University Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will test an investigational drug, theophylline, in children with
      pseudohypoparathyroidism type 1a (PHP1a). This study involves a 3 day visit to the
      Vanderbilt Clinical Research Center.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study measures will be done at baseline and during a 24h infusion of IV theophylline.
      Theophylline levels will be drawn to ensure therapeutic dosing and to monitor for toxicity.
      Measures include laboratory values, response to PTH infusion and resting energy expenditure.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2015</start_date>
  <completion_date type="Actual">October 2016</completion_date>
  <primary_completion_date type="Actual">October 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Urine cAMP</measure>
    <time_frame>1 day</time_frame>
    <description>Change in urine cAMP (after parathyroid hormone stimulation) before and during treatment with theophylline</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Resting Energy Expenditure (REE)</measure>
    <time_frame>1 day</time_frame>
    <description>Change in REE before and during treatment with theophylline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apnea Hypopnea Index (AHI)</measure>
    <time_frame>1 day</time_frame>
    <description>Change in AHI before and during treatment with theophylline</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">6</enrollment>
  <condition>Pseudohypoparathyroidism Type 1a</condition>
  <condition>Albright Hereditary Osteodystrophy</condition>
  <arm_group>
    <arm_group_label>Theophylline</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive a 24 hour continuous infusion of intravenous theophylline.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Theophylline</intervention_name>
    <description>24 hour infusion of IV theophylline</description>
    <arm_group_label>Theophylline</arm_group_label>
    <other_name>Theo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age 10 to 21 years old

          2. English proficiency

          3. Clinical and genetic diagnosis of PHP1a

        Exclusion Criteria:

          1. Use of a PDE inhibitor in the past 30 days

          2. History of a seizure disorder unrelated to hypocalcemia

          3. History of a cardiac arrhythmia (not including bradycardia)

          4. History of hepatic insufficiency

          5. AST or ALT &gt;2x upper limit of normal

          6. Total bilirubin &gt;1.5 x upper limit of normal (unless patient has a diagnosis of
             Gilbert's syndrome and no other causes leading to hyperbilirubinemia are identified)

          7. Congestive heart failure

          8. Cigarette use in the past 30 days

          9. Alcohol use within the past 24 hours

         10. Current pregnancy

         11. Untreated hypothyroidism (defined as free T4 level &lt; 0.6 ng/dL or TSH &gt;10 mcU/mL)

         12. Active peptic ulcer disease

         13. Fever &gt;101 degrees in the past 24 hours

         14. Current use of medications known to effect theophylline levels (listed below)

         15. Severe sleep apnea requiring BiPAP

        Drugs with clinically significant drug interactions with theophylline:

          -  Allopurinol

          -  Cimetidine

          -  Ciprofloxacin

          -  Clarithromycin

          -  Enoxacin

          -  Ephedrine

          -  Erythromycin

          -  Estrogen

          -  Flurazepam

          -  Fluvoxamine

          -  Lithium

          -  Lorazepam

          -  Methotrexate

          -  Midazolam

          -  Pentoxifylline

          -  Propranolol

          -  Rifampin

          -  Sulfinpyrazone

          -  Tacrine

          -  Thiabendazole

          -  Ticlopidine

          -  Troleandomycin

          -  Verapamil
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>10 Years</minimum_age>
    <maximum_age>21 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ashley H Shoemaker, MD, MSCI</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vanderbilt University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Vanderbilt Unversity</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.facebook.com/pseudohypoparathyroidism</url>
    <description>Vanderbilt PHP Research Page</description>
  </link>
  <reference>
    <citation>Landreth H, Malow BA, Shoemaker AH. Increased Prevalence of Sleep Apnea in Children with Pseudohypoparathyroidism Type 1a. Horm Res Paediatr. 2015;84(1):1-5. doi: 10.1159/000381452. Epub 2015 Apr 23.</citation>
    <PMID>25925491</PMID>
  </reference>
  <reference>
    <citation>Shoemaker AH, Lomenick JP, Saville BR, Wang W, Buchowski MS, Cone RD. Energy expenditure in obese children with pseudohypoparathyroidism type 1a. Int J Obes (Lond). 2013 Aug;37(8):1147-53. doi: 10.1038/ijo.2012.200.</citation>
    <PMID>23229731</PMID>
  </reference>
  <verification_date>January 2017</verification_date>
  <lastchanged_date>January 17, 2017</lastchanged_date>
  <firstreceived_date>May 20, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Vanderbilt University Medical Center</investigator_affiliation>
    <investigator_full_name>Ashley Shoemaker</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Pseudohypoparathyroidism</mesh_term>
    <mesh_term>Pseudopseudohypoparathyroidism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Theophylline</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Investigators may contact Dr. Shoemaker for data after our primary analysis is completed and published (if applicable).</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
